Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant - Archive ouverte HAL Access content directly
Journal Articles eJHaem Year : 2022

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

(1) , (2) , (3) , (1) , (3) , (1) , (1) , (1) , (2) , (3) , (3) , (1) , (1) , (3, 4) , (3) , (3, 1)
1
2
3
4

Abstract

The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.
Fichier principal
Vignette du fichier
2022 (eJHaem) Anti‐SARS‐CoV‐2 vaccines in recipient and or donor before allotransplant.pdf (203 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03580755 , version 1 (18-02-2022)

Identifiers

Cite

Maxime Jullien, Marianne Coste‐burel, Beatrice Clemenceau, Valentin Letailleur, Thierry Guillaume, et al.. Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant. eJHaem, 2022, ahead of print. ⟨10.1002/jha2.398⟩. ⟨inserm-03580755⟩
49 View
54 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More